NZ706862A - Agent for preventing or improving decline in brain function - Google Patents
Agent for preventing or improving decline in brain functionInfo
- Publication number
- NZ706862A NZ706862A NZ706862A NZ70686213A NZ706862A NZ 706862 A NZ706862 A NZ 706862A NZ 706862 A NZ706862 A NZ 706862A NZ 70686213 A NZ70686213 A NZ 70686213A NZ 706862 A NZ706862 A NZ 706862A
- Authority
- NZ
- New Zealand
- Prior art keywords
- decreased
- agent
- preventing
- salt
- brain function
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012238541 | 2012-10-30 | ||
| PCT/JP2013/080052 WO2014069666A1 (en) | 2012-10-30 | 2013-10-30 | Agent for preventing or improving decline in brain function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ706862A true NZ706862A (en) | 2019-03-29 |
Family
ID=50627558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ706862A NZ706862A (en) | 2012-10-30 | 2013-10-30 | Agent for preventing or improving decline in brain function |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10369186B2 (enExample) |
| EP (1) | EP2914257B1 (enExample) |
| JP (1) | JP6170166B2 (enExample) |
| AU (1) | AU2013339057B2 (enExample) |
| CA (1) | CA2888791C (enExample) |
| ES (1) | ES2728471T3 (enExample) |
| NZ (1) | NZ706862A (enExample) |
| WO (1) | WO2014069666A1 (enExample) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1110392A (en) * | 1964-09-28 | 1968-04-18 | Yamanouchi Pharma Co Ltd | Composition containing glutathione and an amino acid or amino acids, and salts thereof |
| US20010056068A1 (en) * | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
| CA2421885A1 (en) * | 2000-10-27 | 2002-05-02 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| WO2003026684A1 (en) | 2001-09-27 | 2003-04-03 | The Mental Health Research Institute Of Victoria | Modulation of physiological processes and agents useful for same |
| US20060046982A1 (en) | 2004-08-26 | 2006-03-02 | Waugh William H | Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease |
| JP4137906B2 (ja) * | 2005-03-30 | 2008-08-20 | ピアス株式会社 | セラミダーゼ阻害剤 |
| US20090047340A1 (en) * | 2006-03-29 | 2009-02-19 | Guilford F Timothy | Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis |
| US8597640B2 (en) | 2007-10-31 | 2013-12-03 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
| CA2709660C (en) * | 2008-01-04 | 2018-06-05 | Nestec S.A. | Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions |
| JP5931325B2 (ja) * | 2008-01-30 | 2016-06-08 | 協和発酵バイオ株式会社 | 注意集中力向上剤 |
| WO2009099132A1 (ja) * | 2008-02-05 | 2009-08-13 | Kyowa Hakko Bio Co., Ltd. | グルタチオンの保存安定性向上方法 |
| JP2010126462A (ja) * | 2008-11-26 | 2010-06-10 | Mitsubishi Gas Chemical Co Inc | 脳機能改善用組成物および該組成物を含有する機能性食品 |
-
2013
- 2013-10-30 AU AU2013339057A patent/AU2013339057B2/en active Active
- 2013-10-30 WO PCT/JP2013/080052 patent/WO2014069666A1/en not_active Ceased
- 2013-10-30 US US14/435,679 patent/US10369186B2/en active Active
- 2013-10-30 ES ES13851411T patent/ES2728471T3/es active Active
- 2013-10-30 CA CA2888791A patent/CA2888791C/en active Active
- 2013-10-30 NZ NZ706862A patent/NZ706862A/en unknown
- 2013-10-30 JP JP2015538828A patent/JP6170166B2/ja active Active
- 2013-10-30 EP EP13851411.2A patent/EP2914257B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10369186B2 (en) | 2019-08-06 |
| EP2914257A4 (en) | 2016-07-27 |
| CA2888791C (en) | 2021-07-27 |
| WO2014069666A1 (en) | 2014-05-08 |
| JP6170166B2 (ja) | 2017-07-26 |
| AU2013339057A1 (en) | 2015-04-30 |
| US20150265670A1 (en) | 2015-09-24 |
| EP2914257B1 (en) | 2019-04-03 |
| CA2888791A1 (en) | 2014-05-08 |
| ES2728471T3 (es) | 2019-10-24 |
| EP2914257A1 (en) | 2015-09-09 |
| AU2013339057B2 (en) | 2018-08-30 |
| JP2015535240A (ja) | 2015-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN01198A (enExample) | ||
| PH12015500561A1 (en) | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | |
| MX379044B (es) | Direccion de elementos reguladores distales de bcl11a para reinduccion de hemoglobina fetal. | |
| MA37975A1 (fr) | Inhibiteurs de synthase de glucosylcéramide | |
| CR20150174A (es) | Composición esterilizada que comprende al menos un ácido hialuronico y ascorbil fosfato de magnesio | |
| NZ707081A (en) | Agent for preventing or improving decline in brain function | |
| PH12015500900A1 (en) | A stabilized pemetrexed formulation | |
| BR112015023987A2 (pt) | creme dental de duas fases | |
| EA201201239A1 (ru) | Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением | |
| MX2014016121A (es) | Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular. | |
| BR112014029264A2 (pt) | microcápsulas contendo um oxidável ativa, e um processo para a preparação do mesmo | |
| PH12016501005A1 (en) | Anti-malodor oral care composition | |
| MX2015005284A (es) | Control de niveles de dioxido de carbono y ph en reactores de pequeños volumenes,. | |
| IN2014KN02914A (enExample) | ||
| JP2015535241A5 (enExample) | ||
| GB2521979A (en) | A method, use, and dietary supplement composition for at least treating an atopic or non-atopic disorder in a patient | |
| IN2014KN02745A (enExample) | ||
| MX341189B (es) | Composicion liquida y acousa de bromfenaco, que tiene efectividad conservadora. | |
| WO2012068038A3 (en) | Caffeic acid derivatives and their use in improving neuronal cell viability | |
| WO2014031982A3 (en) | Methods and compositions for treating pain | |
| MY170840A (en) | Aqueous composition containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid | |
| HK1203379A1 (en) | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | |
| WO2015001524A3 (en) | Stabilization of rose dedifferentiated cells | |
| PH12013500497A1 (en) | Composition for improving brain function and method for improving brain function | |
| JP2015535240A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2020 BY CPA GLOBAL Effective date: 20190912 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2021 BY CPA GLOBAL Effective date: 20200917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2022 BY CPA GLOBAL Effective date: 20210916 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2023 BY CPA GLOBAL Effective date: 20220915 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2024 BY CPA GLOBAL Effective date: 20230914 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240912 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250918 |